Activity Summary:
To further build on the insights presented in the Clinical Clips® from EASL Congress 2026: Key Breakthroughs in the Treatment of PBC by Dr. Kris Kowdley, HCPs can access a range of downloadable resources designed to reinforce key concepts and support practical application in clinical care.

Available Resources:

Downloadable Slide Deck (PDF)
Downloadable version of the presentation slides used by the faculty, including data visuals, figures, and key discussion points.

Expert Commentary Transcript
A transcript of the podcast version of the program, reflecting the expert discussion and interpretation of EASL 2026 data.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies.

Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast format, listeners will gain practical insights into how new evidence can inform personalized treatment strategies, support improved patient outcomes, and enhance the overall quality of care for people living with PBC.

Activity Summary:
These videos provide a concise overview of the latest clinical developments in Primary Biliary Cholangitis presented at EASL Congress 2026. Expert faculty discuss emerging evidence that is shaping the evolving treatment landscape and what these updates may mean for clinical practice.

Watch to gain practical insights into applying the newest data to personalized patient management, with the goal of improving outcomes and advancing the quality of care for individuals living with PBC.

Activity Summary:

Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This podcast will utilize a case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC. 

Activity Summary:
Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This program will utilize case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC.

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:
There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from EASL 2025 and describe their implications for clinical practice. 

Activity Summary:

We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXXIII (OPMAN). The conference took place March 22-23, 2025, in Washington, D.C., with leading clinicians and researchers presenting an array of topics covering HIV disease and liver disease. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These accredited video archives of OPMAN XXXIII provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience questions. Continuing education credit is provided for each segment, so you may participate in your area(s) of interest. We hope you enjoy this activity!

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.

Activity Summary:
This podcast series features engaging discussions between leading experts and their patients with primary biliary cholangitis (PBC). The patients share their insights and experiences with PBC, its treatment, and key learning experiences in their journeys with PBC. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at AASLD 2024. In these video Clips, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.

Activity Summary:

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this series of Clinical Clips, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXXII (OPMAN). The conference took place March 16-17, 2024, in Baltimore, Maryland with leading clinicians and researchers presenting an array of topics covering HIV disease and liver disease. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These accredited video archives of OPMAN XXXII provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience questions. Continuing education credit is provided for each segment, so you may participate in your area(s) of interest. We hope you enjoy this activity!

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXXI (OPMAN). The conference took place March 18-19, 2023, in Orlando, Florida with 15 leading clinicians and researchers presenting an array of topics covering HIV disease and liver disease. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These accredited enduring video archives of OPMAN XXXI provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience questions. CME/CE credit is provided separately by section so you can participate in only those sections of interest to you. We hope you enjoy this activity.

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXX (OPMAN). The conference took place March 26-27, 2022, in Orlando, Florida with 15 leading clinicians and researchers presenting an array of topics covering HIV disease and liver disease. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These accredited enduring video archives of OPMAN XXX provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience questions. CME/CE credit is provided separately by section so you can participate in only those sections of interest to you. We hope you enjoy this activity.

Activity Summary:
HBV is a most common causes of liver cirrhosis and HCC. Curing persons with HBV infection remains elusive, despite the availablility of effective antiviral therapy. However, the urgency for an HBV cure remains an active area of research. This program will discuss key research advances in the strategies to HBV cure, pros and cons of withdrawal of therapy, and novel antiviral/immunomodulatory therapies.

Dr. Nezam Afdhal and Dr. Daryl Lau will lead each of the 15-minute segment presentations with downloadable, supporting PowerPoint slides. Each segment will be available for .25 AMA/ANCC/ACPE credit/contact hour based on confirmed participation and the completion of an evaluation and post-test.

Activity Summary:
This educational archived webcast features Dr. Joseph Lim and Dr. Nancy Reau presenting current cases and topics on today's HCV patient.

Activity Summary:
This educational archived webcast features Dr. Robert Brown and Dr. Anthony Martinez presenting current cases and topics on today's HCV patient.

Activity Summary:
These educational presentations will focus on issues related to HCV elimination among Appalachian community care providers. Topics discussed include approaches to identify patients at high risk, HCV screening and management strategies for persons who inject drugs and incarcerated persons, and gaps in the HCV care continuum and key tools that community healthcare professionals can use to achieve elimination goals within a clinical practice.

Dr. Sally Hodder and Dr. Alice Thornton will lead each of the 1-hour presentations along with a community expert in the each of the Appalachian regions. The webcast archive will be available for 1 AMA/ANCC/ACPE credit/contact hour(s) based on confirmed participation and the completion of an evaluation and posttest.

Activity Summary:
This educational archive features Dr. Mark Sulkowski and Dr. Stacey Trooskin presenting topics on today's HCV patient using cases submitted by the audience.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

The national strategy for the elimination of HCV in the United States calls for a 90% reduction in the incidence of HCV and having 90% of those with HCV being treated. Scaling up HCV treatment in persons who inject drugs (PWIDs) and persons who are incarcerated is necessary to achieve HCV elimination targets.

These slides will review important issues for PWIDs and the incarcerated with HCV, including epidemiologic trends, prevention strategies, and AASLD recommendations for contemporary HCV management approaches/challenges and harm-reduction approaches.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Critical to achieving the elimination of HCV infection is identifying HIV-infected persons with improved screening and surveillance approaches and linking them to HCV care and treatment. These steps will reduce the incidence of HCV, cirrhosis, HCC, liver-related deaths, and retransmission of HCV. These slides will review the changing epidemiology/ demographics of HCV infection and burden of disease and discusses screening and linkage-to-care approaches important to achieving the elimination of HCV infection in the United States.

Activity Summary:
Patient Perspectives in HCV is an educational podcast comprising a series of episodes released throughout the year.

These interview-based podcasts will focus on the patient's life experience with HCV infection, including diagnosis, interactions with healthcare providers, top treatment concerns, and how life changed since being cured. The series will also discuss approaches to improve HCV outcomes based on lessons learned from these patient perspectives.